- Home
- WINT vs SNES Comparison
WINT vs SNES Comparison
Compare WINT & SNES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WINT
- SNES
- Stock Information
- Founded
- WINT 1992
- SNES 2004
- Country
- WINT United States
- SNES United States
- Employees
- WINT N/A
- SNES N/A
- Industry
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- SNES Agricultural Chemicals
- Sector
- WINT Health Care
- SNES Industrials
- Exchange
- WINT Nasdaq
- SNES Nasdaq
- Market Cap
- WINT 2.9M
- SNES 2.3M
- IPO Year
- WINT 1995
- SNES 2016
- Fundamental
- Price
- WINT $0.31
- SNES $3.11
- Analyst Decision
- WINT Hold
- SNES Strong Buy
- Analyst Count
- WINT 1
- SNES 1
- Target Price
- WINT $7.00
- SNES $10.00
- AVG Volume (30 Days)
- WINT 1.2M
- SNES 321.5K
- Earning Date
- WINT 11-27-2024
- SNES 11-12-2024
- Dividend Yield
- WINT N/A
- SNES N/A
- EPS Growth
- WINT N/A
- SNES N/A
- EPS
- WINT N/A
- SNES N/A
- Revenue
- WINT N/A
- SNES $1,651,000.00
- Revenue This Year
- WINT N/A
- SNES $76.36
- Revenue Next Year
- WINT N/A
- SNES $103.47
- P/E Ratio
- WINT N/A
- SNES N/A
- Revenue Growth
- WINT N/A
- SNES 38.16
- 52 Week Low
- WINT $0.32
- SNES $1.90
- 52 Week High
- WINT $14.75
- SNES $21.40
- Technical
- Relative Strength Index (RSI)
- WINT 28.66
- SNES 50.79
- Support Level
- WINT $0.33
- SNES $2.32
- Resistance Level
- WINT $0.42
- SNES $5.00
- Average True Range (ATR)
- WINT 0.03
- SNES 0.57
- MACD
- WINT 0.02
- SNES -0.00
- Stochastic Oscillator
- WINT 1.91
- SNES 21.82
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
About SNES SenesTech Inc.
SenesTech Inc is a United States-based biotech platform and research company engaged in developing technology for managing animal pest populations through fertility control. The company provides its solutions to the animal market, commercial markets, and food markets. It currently has two product lines of fertility control products: ContraPest and Evolve.